RS20050857A - DERIVATI AZAINDOLA KAO INHIBITORI Xa FAKTORA - Google Patents

DERIVATI AZAINDOLA KAO INHIBITORI Xa FAKTORA

Info

Publication number
RS20050857A
RS20050857A YUP-2005/0857A YUP20050857A RS20050857A RS 20050857 A RS20050857 A RS 20050857A YU P20050857 A YUP20050857 A YU P20050857A RS 20050857 A RS20050857 A RS 20050857A
Authority
RS
Serbia
Prior art keywords
alkyl
residue
alkylene
substituted
unsubstituted
Prior art date
Application number
YUP-2005/0857A
Other languages
English (en)
Serbian (sr)
Inventor
Marc Nazare
Volkmar Wehner
David William Will
Kurt Ritter
Matthias Urmann
Hans Matter
Original Assignee
Sanofi-Aventis Deutschland Gmbh.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh., filed Critical Sanofi-Aventis Deutschland Gmbh.,
Publication of RS20050857A publication Critical patent/RS20050857A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
YUP-2005/0857A 2003-05-19 2004-05-05 DERIVATI AZAINDOLA KAO INHIBITORI Xa FAKTORA RS20050857A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011304A EP1479680A1 (en) 2003-05-19 2003-05-19 Azaindole derivatives as Factor Xa inhibitors
PCT/EP2004/004754 WO2004101563A1 (en) 2003-05-19 2004-05-05 AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
RS20050857A true RS20050857A (sr) 2007-11-15

Family

ID=33040951

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0857A RS20050857A (sr) 2003-05-19 2004-05-05 DERIVATI AZAINDOLA KAO INHIBITORI Xa FAKTORA

Country Status (24)

Country Link
EP (2) EP1479680A1 (https=)
JP (1) JP4733642B2 (https=)
KR (1) KR20060012636A (https=)
CN (1) CN100347172C (https=)
AR (1) AR045682A1 (https=)
AU (1) AU2004238500B2 (https=)
BR (1) BRPI0410429A (https=)
CA (1) CA2526084A1 (https=)
CL (1) CL2004001079A1 (https=)
CR (1) CR8088A (https=)
EC (1) ECSP056179A (https=)
MA (1) MA27799A1 (https=)
MX (1) MXPA05012156A (https=)
NO (1) NO20055911L (https=)
NZ (1) NZ543669A (https=)
OA (1) OA13169A (https=)
PE (1) PE20050554A1 (https=)
RS (1) RS20050857A (https=)
RU (1) RU2330853C2 (https=)
TN (1) TNSN05296A1 (https=)
TW (1) TW200510411A (https=)
UA (1) UA86767C2 (https=)
WO (1) WO2004101563A1 (https=)
ZA (1) ZA200508150B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351940T3 (es) * 2005-11-18 2011-02-14 F. Hoffmann-La Roche Ag Derivados de azaindol-2-carboxamida.
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
IN2015DN01061A (https=) 2012-08-17 2015-06-26 Bayer Cropscience Ag
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111834531B (zh) * 2019-04-15 2022-04-19 天津大学 一种有机半导体材料、制备方法及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241472B (it) 1990-07-06 1994-01-17 Olivier Linda Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti.
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
SI9520044B (sl) 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
ZA964008B (en) * 1995-06-02 1997-07-11 Akzo Nobel Nv Imidazo[1,5a]pyridine derived serine protease inhibitors
EP1040108B1 (en) * 1997-12-19 2004-02-25 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
HU227568B1 (en) * 1997-12-24 2011-08-29 Sanofi Aventis Deutschland Indole derivatives, as inhibitors os factor xa
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE60040676D1 (de) * 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US6790845B2 (en) * 2001-04-09 2004-09-14 Bristol-Myers Squibb Pharma Company Fused heterocyclic inhibitors of factor Xa
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
KR100960827B1 (ko) * 2001-12-20 2010-06-08 오에스아이 파마슈티컬스, 인코포레이티드 피롤로피리미딘 Ａ₂ｂ 선택성 길항 화합물, 그의 합성방법 및 용도
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
JP4733642B2 (ja) 2011-07-27
OA13169A (en) 2006-12-13
JP2006528214A (ja) 2006-12-14
AU2004238500A1 (en) 2004-11-25
KR20060012636A (ko) 2006-02-08
EP1479680A1 (en) 2004-11-24
MXPA05012156A (es) 2006-08-18
MA27799A1 (fr) 2006-03-01
NO20055911L (no) 2006-02-10
AU2004238500B2 (en) 2010-07-22
TNSN05296A1 (en) 2007-07-10
ZA200508150B (en) 2007-02-28
HK1089175A1 (zh) 2006-11-24
RU2005139557A (ru) 2007-06-27
CA2526084A1 (en) 2004-11-25
CN100347172C (zh) 2007-11-07
BRPI0410429A (pt) 2006-06-06
CR8088A (es) 2006-09-22
CL2004001079A1 (es) 2005-04-08
UA86767C2 (ru) 2009-05-25
RU2330853C2 (ru) 2008-08-10
WO2004101563A1 (en) 2004-11-25
NZ543669A (en) 2008-12-24
EP1636226B1 (en) 2014-10-15
CN1791601A (zh) 2006-06-21
AR045682A1 (es) 2005-11-09
PE20050554A1 (es) 2005-08-04
ECSP056179A (es) 2006-08-30
EP1636226A1 (en) 2006-03-22
TW200510411A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
AU2004238495B2 (en) New indole derivatives as factor Xa inhibitors
US20080280946A1 (en) Azaindole-Derivatives As Factor Xa Inhibitors
WO2004101556A1 (en) INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
EP1725550A2 (en) Pyrrole-derivatives as factor xa inhibitors
AU2004238498B2 (en) Triazole-derivatives as factor Xa inhibitors
US20050009829A1 (en) Benzimidazole-derivatives as factor Xa inhibitors
RU2346944C2 (ru) ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
RS20050857A (sr) DERIVATI AZAINDOLA KAO INHIBITORI Xa FAKTORA
EP1479674A1 (en) Imidiazole-derivatives as factor xa inhibitors